News
ROSEN, LEADING INVESTOR COUNSEL, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - POM
Rosen Law Firm has filed a class action lawsuit against PomDoctor Ltd. (NASDAQ: POM) on behalf of investors who purchased securities between October 9, 2025 and December 11, 2025. The lawsuit alleges that defendants made false and misleading statements regarding a fraudulent stock promotion scheme involving social media misinformation, insider share dumping through offshore accounts, and omitted risk disclosures. Investors who wish to serve as lead plaintiff must file by April 7, 2026.
Should You Buy Nvidia Stock Before Feb. 25? Here's What History Says.
Nvidia is set to report Q4 2026 earnings on Feb. 25. The article argues that long-term investors should focus on the company's strong fundamentals rather than short-term earnings volatility. With record revenue of $57 billion, 92% GPU market share, a powerful economic moat, and a reasonable forward P/E ratio of 22, Nvidia remains an excellent buy-and-hold investment despite recent tech sector sell-offs.
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis
TG Therapeutics announced a collaboration with actress Christina Applegate, who has lived with MS for 5 years, to raise awareness and support meaningful conversations for people living with multiple sclerosis. The partnership launched a new platform called www.NextInMS.com during Super Bowl LX, featuring Christina's personal perspectives and expert educational content designed to foster open dialogue among MS patients, caregivers, and healthcare professionals.
How Does IEMG's Emerging Markets Potential Compare to SPGM's Global Exposure?
IEMG and SPGM are two ETFs offering different investment approaches: IEMG focuses exclusively on emerging markets with higher recent returns (37.83% in 1-year) but greater volatility, while SPGM provides broader global exposure including U.S. stocks with more consistent long-term growth. Both have identical expense ratios of 0.09%, but investors should choose based on their risk tolerance and investment timeline.
Novo Nordisk Plunges Nearly 15% After Earnings. Here's What Investors Need to Know.
Novo Nordisk's stock fell nearly 15% after reporting weak 2026 guidance with expected sales and earnings declines of 5-13%, driven by lower GLP-1 drug pricing from a U.S. government agreement. However, the company's new GLP-1 pill exceeded expectations with 170,000 patients in just four weeks, suggesting strong long-term volume potential that could offset near-term pricing pressures.